Personalis Total Long Term Liabilities 2018-2024 | PSNL

Personalis total long term liabilities from 2018 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Personalis Annual Total Long Term Liabilities
(Millions of US $)
2023 $48
2022 $41
2021 $55
2020 $9
2019 $1
2018 $90
2017 $
Personalis Quarterly Total Long Term Liabilities
(Millions of US $)
2024-09-30 $37
2024-06-30 $39
2024-03-31 $43
2023-12-31 $48
2023-09-30 $43
2023-06-30 $44
2023-03-31 $44
2022-12-31 $41
2022-09-30 $42
2022-06-30 $52
2022-03-31 $54
2021-12-31 $55
2021-09-30 $55
2021-06-30 $11
2021-03-31 $9
2020-12-31 $9
2020-09-30 $9
2020-06-30 $9
2020-03-31 $1
2019-12-31 $1
2019-09-30 $1
2019-06-30 $18
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.396B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $24.935B 8.18
Dr Reddy's Laboratories (RDY) India $12.596B 24.10
BridgeBio Pharma (BBIO) United States $6.773B 0.00
Bausch Health Cos (BHC) Canada $2.792B 2.06
Supernus Pharmaceuticals (SUPN) United States $2.108B 28.70
Amphastar Pharmaceuticals (AMPH) United States $1.738B 10.44
Taysha Gene Therapies (TSHA) United States $0.314B 21.86
Assembly Biosciences (ASMB) United States $0.095B 0.00
Sol-Gel Technologies (SLGL) Israel $0.025B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00